Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer
Clinical trial NCT04900311 · UNKNOWN
Trial details
- NCT number
- NCT04900311
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-01
- Primary completion
- 2023-12-01
- Enrollment
- 490
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.